You searched for
Tag:
Innovation
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
23/06/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
24/02/2023
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22/02/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17/01/2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
04/12/2022
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21/11/2022
Chiesi Group continues to grow
31/03/2022
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14/12/2021
Chiesi receives positive ESG rating from independent rating agency Cerved
23/09/2021
ERS Congress 2021 – Important updates on Asthma and COPD treatments presented at the Symposium organised by Chiesi “Unlock Every Breath: finding the right key to improve Respiratory Therapy”
06/09/2021